Tectonic Therapeutic Inc (TECX) Stock Price, Quote & News

Company Profile

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 339 666 3320

Website: tectonictx.com

Address:

490 Arsenal Way, Suite 210, Watertown, United States

Vertical_Capital Sep. 9 at 5:35 PM

$CRMD Algo just eating shares up $TECX Keep your eyes on this...cheap and all Price Targets $60-$80 @ $17.40 on stupid selloff ...will retrace to $20 quickly $OPEN $BABA $NBIS

0 · Reply

Avj90 Sep. 9 at 10:36 AM

$TECX when 7?

0 · Reply

NVDAMillionaire Sep. 9 at 8:25 AM

$TECX Brilliant piece that captures TECX's situation perfectly. So if you want to update your understanding of TECX or get to know TECX better, this is essential reading. https://beyondspx.com/quote/TECX/analysis/tectonic-therapeutic-s-geode-platform-unlocking-gpcr-potential-in-a-competitive-biotech-arena-nasdaq-tecx

0 · Reply

valueforme Sep. 4 at 2:44 PM

$TECX It was a nice rug pull right at the opening, I was not able to add. But now all eyes on what the CEO says at Cantor in several hours

0 · Reply

valueforme Sep. 4 at 1:00 AM

$TECX @RonIsWrong wdyt, both bought or else?

1 · Reply

Yoman73 Sep. 3 at 6:29 PM

$TECX im buying

0 · Reply

JarvisFlow Sep. 3 at 4:36 PM

Oppenheimer has adjusted their stance on Tectonic Therapeutic ( $TECX ), setting the rating to Outperform with a target price of 80.

0 · Reply

StocktwitsNews Sep. 3 at 12:02 PM

Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate $TECX $IWMW $VTWG https://stocktwits.com/news/equity/markets/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m

0 · Reply

Cracker36 Sep. 3 at 11:33 AM

$TECX gonna bounce hard this morning

0 · Reply

Stmkr Sep. 3 at 10:46 AM

$TECX LLY asset used albumin-binding to extend half-life. Fc-fusion by TECX much much better pk and potentially (?) better hemodynamic effects in pulmonary vasculature. LLY study also focused on HFpEF with recent (within 2w) decompensation. TECX ph2 focuses on PH-HFpEF with enrichment for patients with high PVR (established pulmonary vasculature damage). AZN readout maybe later this year. Similar Fc-fusion tech but q2w vs q4w dosing. Broader PH-HF population. Readout more likely to reflecr TX45 potential

0 · Reply

Tectonic Therapeutic to Participate in September Investor Conferences

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Tectonic Therapeutic Joins Russell 3000® Index

May 17, 2025, 10:40 AM EDT - 4 months ago

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

May 8, 2025, 4:01 PM EDT - 4 months ago

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

Apr 23, 2025, 5:51 AM EDT - 5 months ago

Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF

Mar 20, 2025, 4:01 PM EDT - 6 months ago

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 5, 2025, 11:36 AM EST - 7 months ago

Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data

Feb 3, 2025, 6:30 AM EST - 7 months ago

Tectonic Announces $185 Million Private Placement

Jan 30, 2025, 6:30 AM EST - 8 months ago

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

Jan 5, 2025, 7:30 AM EST - 8 months ago

Tectonic Therapeutic: Protein Engineering Platform For GPCRs

Dec 3, 2024, 4:01 PM EST - 10 months ago

Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024

Nov 26, 2024, 4:01 PM EST - 10 months ago

Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference

Nov 11, 2024, 5:00 AM EST - 10 months ago

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein

Oct 22, 2024, 4:01 PM EDT - 11 months ago

Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

Oct 20, 2024, 6:02 AM EDT - 11 months ago

Tectonic Therapeutic: Interesting CV Disease Drug Developer

Sep 19, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 30, 2024, 4:01 PM EDT - 1 year ago

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

Vertical_Capital Sep. 9 at 5:35 PM

$CRMD Algo just eating shares up $TECX Keep your eyes on this...cheap and all Price Targets $60-$80 @ $17.40 on stupid selloff ...will retrace to $20 quickly $OPEN $BABA $NBIS

0 · Reply

Avj90 Sep. 9 at 10:36 AM

$TECX when 7?

0 · Reply

NVDAMillionaire Sep. 9 at 8:25 AM

0 · Reply

valueforme Sep. 4 at 2:44 PM

$TECX It was a nice rug pull right at the opening, I was not able to add. But now all eyes on what the CEO says at Cantor in several hours

0 · Reply

valueforme Sep. 4 at 1:00 AM

$TECX @RonIsWrong wdyt, both bought or else?

1 · Reply

Yoman73 Sep. 3 at 6:29 PM

$TECX im buying

0 · Reply

JarvisFlow Sep. 3 at 4:36 PM

Oppenheimer has adjusted their stance on Tectonic Therapeutic ( $TECX ), setting the rating to Outperform with a target price of 80.

0 · Reply

StocktwitsNews Sep. 3 at 12:02 PM

0 · Reply

Cracker36 Sep. 3 at 11:33 AM

$TECX gonna bounce hard this morning

0 · Reply

Stmkr Sep. 3 at 10:46 AM

0 · Reply

Khanstocks Sep. 2 at 11:36 PM

$TECX wonder if we get some clarity from the fireside chat

1 · Reply

vessp312 Sep. 2 at 11:04 PM

$TECX update: sold 17.85, bought back in 17.10 this will be 20+ in day or two

0 · Reply

Jabed206 Sep. 2 at 10:44 PM

$TECX This SP action is taking the piss

0 · Reply

Khanstocks Sep. 2 at 9:40 PM

$TECX selloff overdone

1 · Reply

valueforme Sep. 2 at 9:25 PM

$TECX Borlaug, B.A., Testani, J.M., Petrie, M.C. et al. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Nat Med (2025). https://doi.org/10.1038/s41591-025-03939-6 Received: 09 July 2025 Accepted: 05 August 2025 Published: 31 August 2025

1 · Reply

valueforme Sep. 2 at 8:14 PM

$TECX AZN NHP data "Measurement of potential biomarkers affected by AZD3427 revealed a significant and dose-dependent increase in plasma renin levels in NHP with maintained exposure" So, if LLY's drug congestion was a result of RAAS activation, then we have NHP evidence for AZD3427 that this could be avoided. Note that TECX molecule is much much closer to AZN one than to LLY one https://academic.oup.com/cardiovascres/article/121/6/871/8050098

1 · Reply

valueforme Sep. 2 at 6:57 PM

$TECX Take it with a grain of salt , but it's way to early to kill the whole class based on Lilly's trial

2 · Reply

Stmkr Sep. 2 at 6:25 PM

$TECX Very Interesting after this dip. Last offering at the peak at around $50. Seems to be an overreaction to LLY data

0 · Reply

stocksense2 Sep. 2 at 5:22 PM

$TECX Is this an over reaction?

1 · Reply

valueforme Sep. 2 at 3:38 PM

$TECX Burning around $20-25M per quarter. Projected end of Q3 cash - $265M. This is $265/18.7 = $14.17 of cash per share for the moment in time when 1b full results will be published. Pipeline is currently valued at 3 bucks per share. AZN's AZD3427 readout very soon.

0 · Reply

Jabed206 Sep. 2 at 3:14 PM

$TECX eating up shares...

0 · Reply

Jabed206 Sep. 2 at 2:58 PM

$TECX love how people make assumptions

0 · Reply

Market Cap	337.38M
Revenue (ttm)	0.00
Net Income (ttm)	-57.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	331,000
Avg Vol	321,276
Day's Range	N/A - N/A
Shares Out	18.71M
Stochastic %K	54%
Beta	3.42
Analysts	Strong Sell
Price Target	$79.75